United States · Funded startup

Who invested in Elixirgen Therapeutics

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 15 Nov 2026

$4.0Mraised across 1 round since 2025, from 1 source

Latest round
Round, $4.0MOct 2025
Investors
0
See who backed them

The rounds

  1. Oct 2025
    Round$4.0M

    No investor was named in the report.

    Filed with the SEC (Form D); no report of this raise yetSEC filing: $4.0M sold, first sale Oct 2025

Funding filed with regulators

Elixirgen Therapeutics filed 8 raises, $34M in all. Filings say how much was sold and to how many investors; they never name the investors.

  1. Oct 2025$4.0M1 investorSEC Form D
  2. Mar 2025$3.6M2 investorsSEC Form D
  3. Jan 2025$600K2 investorsSEC Form D
  4. Nov 2023$7.0M1 investorequitySEC Form D
  5. Sept 2022$5.0M1 investordebtSEC Form D
  6. Feb 2021$4.2M2 investorsequityof $5.5M offeredSEC Form D
  7. Nov 2019$5.7M3 investorsequitySEC Form D
  8. Jun 2018$4.0M1 investorequitySEC Form D

Founders and team

From Elixirgen Therapeutics's own website: 1 founder, 2 on the team.

Aki KoChief Executive Officer & Co-Founder, Board Chairman
  • Shauna CallahanBoard Member
  • Telomere Biology DisordersLead Indication

Quick answers about Elixirgen Therapeutics

How much has Elixirgen Therapeutics raised?

Elixirgen Therapeutics has raised $4.0M across 1 round since 2025.

When did Elixirgen Therapeutics last raise?

Elixirgen Therapeutics's most recent round, $4.0M, was in Oct 2025.

What was Elixirgen Therapeutics's biggest round?

Its most recent round, $4.0M in Oct 2025, is also its largest on record.

Where is Elixirgen Therapeutics based?

Elixirgen Therapeutics is based in the United States.

Companies like Elixirgen Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.